Abstract
Asthma is a result of heterogenous, complex gene–environment interactions with variable clinical phenotypes, inflammation, and remodeling. It affects more than 330 million of people worldwide throughout their educational and working lives, while exacerbations put a heavy cost/burden on productivity. Childhood asthma is characterized by a predominance of allergic sensitization and multimorbidity, while in adults polysensitization has been positively associated with asthma occurrence. Despite significant improvements in recent decades, asthma management remains challenging. Recently, a group of specialists suggested that the term “asthma” should be preferably used as a descriptive term for symptoms. Moreover, type 2 inflammation has emerged as a pivotal disease mechanism including overlapping endotypes of specific IgE production, while type 2-low asthma includes several disease endotypes. Optimal asthma control requires both appropriate pharmacological interventions, tailored to each patient, as well as trigger avoidance measures. Regular monitoring for maintenance of symptom control, preservation of lung function, and detection of treatment-related adverse effects are warranted. Allergen-specific immunotherapy and the advent of new targeted therapies for patients with difficult to control asthma offer diverse treatment options. The current review summarizes up-to-date knowledge on epidemiology, definitions, diagnosis, and current therapeutic strategies.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abramson MJ, Puy RM, Weiner JM (2010) Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 8:CD001186. https://doi.org/10.1002/14651858.CD001186.pub2
Adams N, Lasserson TJ, Cates CJ, Jones PW (2007) Fluticasone versus beclomethasone or budesonide for chronic asthma in adults and children. Cochrane Database Syst Rev 4:CD002310. https://doi.org/10.1002/14651858.CD002310.pub4
Agache I, Lau S, Akdis CA et al (2019) EAACI guidelines on allergen immunotherapy: house dust mite-driven allergic asthma. Allergy 74:855–873. https://doi.org/10.1111/all.13749
Akdis M, Aab A, Altunbulakli C et al (2016) Interleukins (from IL-1 to IL-38), interferons, transforming growth factor beta, and TNF-alpha: receptors, functions, and roles in diseases. J Allergy Clin Immunol 138:984–1010. https://doi.org/10.1016/j.jaci.2016.06.033
Aldrimer M, Ridefelt P, Rodoo P et al (2013) Population-based pediatric reference intervals for hematology, iron and transferrin. Scand J Clin Lab Invest 73:253–261. https://doi.org/10.3109/00365513.2013.769625
Amat F, Labbe A (2018) Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab? Expert Rev Respir Med 12:475–482. https://doi.org/10.1080/17476348.2018.1475233
Anandan C, Nurmatov U, van Schayck OC, Sheikh A (2010) Is the prevalence of asthma declining? Systematic review of epidemiological studies. Allergy 65:152–167. https://doi.org/10.1111/j.1398-9995.2009.02244.x
Anderson DE, Kew KM, Boyter AC (2015) Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus the same dose of ICS alone for adults with asthma. Cochrane Database Syst Rev 8:CD011397. https://doi.org/10.1002/14651858.CD011397.pub2
Andreakos E, Papadopoulos NG (2014) IL-25: the missing link between allergy, viral infection, and asthma? Sci Transl Med 6:256fs38. https://doi.org/10.1126/scitranslmed.3010273
Annunziato F, Romagnani C, Romagnani S (2015) The 3 major types of innate and adaptive cell-mediated effector immunity. J Allergy Clin Immunol 135:626–635. https://doi.org/10.1016/j.jaci.2014.11.001
Bacharier LB, Boner A, Carlsen KH et al (2008) Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy 63:5–34. https://doi.org/10.1111/j.1398-9995.2007.01586.x
Backman H, Raisanen P, Hedman L et al (2017) Increased prevalence of allergic asthma from 1996 to 2006 and further to 2016-results from three population surveys. Clin Exp Allergy 47:1426–1435. https://doi.org/10.1111/cea.12963
Bannier M, Rosias PPR, Jobsis Q, Dompeling E (2019) Exhaled breath condensate in childhood asthma: a review and current perspective. Front Pediatr 7:150. https://doi.org/10.3389/fped.2019.00150
Barlow JL, Flynn RJ, Ballantyne SJ, McKenzie AN (2011) Reciprocal expression of IL-25 and IL-17A is important for allergic airways hyperreactivity. Clin Exp Allergy 41:1447–1455. https://doi.org/10.1111/j.1365-2222.2011.03806.x
Bateman ED, Reddel HK, O’Byrne PM et al (2018) As-needed budesonide-formoterol versus maintenance budesonide in mild asthma. N Engl J Med 378:1877–1887. https://doi.org/10.1056/NEJMoa1715275
Beasley R, Holliday M, Reddel HK et al (2019) Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med 380:2020–2030. https://doi.org/10.1056/NEJMoa1901963
Bel EH, Wenzel SE, Thompson PJ et al (2014) Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med 371:1189–1197. https://doi.org/10.1056/NEJMoa1403291
Bielor C, Sopel N, Maier A et al (2017) Role of TGF-beta in anti-rhinovirus immune responses in asthmatic patients. J Allergy Clin Immunol 140:283–286 e10. https://doi.org/10.1016/j.jaci.2016.10.049
Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89–95. https://doi.org/10.1067/mcp.2001.113989
Bisgaard H, Hermansen MN, Buchvald F et al (2007) Childhood asthma after bacterial colonization of the airway in neonates. N Engl J Med 357:1487–1495. https://doi.org/10.1056/NEJMoa052632
Blanchard C, Mingler MK, McBride M et al (2008) Periostin facilitates eosinophil tissue infiltration in allergic lung and esophageal responses. Mucosal Immunol 1:289–296. https://doi.org/10.1038/mi.2008.15
Bleecker ER, FitzGerald JM, Chanez P et al (2016) Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115–2127. https://doi.org/10.1016/S0140-6736(16)31324-1
Bossios A, Psarras S, Gourgiotis D et al (2005) Rhinovirus infection induces cytotoxicity and delays wound healing in bronchial epithelial cells. Respir Res 6:114. https://doi.org/10.1186/1465-9921-6-114
Bush A (2019) Pathophysiological mechanisms of asthma. Front Pediatr 7:68. https://doi.org/10.3389/fped.2019.00068
Castro M, Zangrilli J, Wechsler ME et al (2015) Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med 3:355–366. https://doi.org/10.1016/S2213-2600(15)00042-9
Castro M, Corren J, Pavord ID et al (2018) Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma. N Engl J Med 378:2486–2496. https://doi.org/10.1056/NEJMoa1804092
Castro-Rodriguez JA, Rodriguez-Martinez CE (2018) Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: a systematic review. Pediatr Pulmonol 53:1670–1677. https://doi.org/10.1002/ppul.24176
Chang Y, Al-Alwan L, Risse PA et al (2012) Th17-associated cytokines promote human airway smooth muscle cell proliferation. FASEB J 26:5152–5160. https://doi.org/10.1096/fj.12-208033
Chauhan BF, Ducharme FM (2012) Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children. Cochrane Database Syst Rev 5:Cd002314. https://doi.org/10.1002/14651858.CD002314.pub3
Chauhan BF, Ducharme FM (2014) Addition to inhaled corticosteroids of long-acting beta2-agonists versus anti-leukotrienes for chronic asthma. Cochrane Database Syst Rev 1:Cd003137. https://doi.org/10.1002/14651858.CD003137.pub5
Chauhan BF, Chartrand C, Ducharme FM (2013) Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2:CD009611. https://doi.org/10.1002/14651858.CD009611.pub3
Chauhan BF, Chartrand C, Ni Chroinin M et al (2015) Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev 11:Cd007949. https://doi.org/10.1002/14651858.CD007949.pub2
Chauhan BF, Jeyaraman MM, Singh Mann A et al (2017) Addition of anti-leukotriene agents to inhaled corticosteroids for adults and adolescents with persistent asthma. Cochrane Database Syst Rev 3:Cd010347. https://doi.org/10.1002/14651858.CD010347.pub2
Cheng D, Xue Z, Yi L et al (2014) Epithelial interleukin-25 is a key mediator in Th2-high, corticosteroid-responsive asthma. Am J Respir Crit Care Med 190:639–648. https://doi.org/10.1164/rccm.201403-0505OC
Chung KF (2015) Targeting the interleukin pathway in the treatment of asthma. Lancet 386:1086–1096. https://doi.org/10.1016/S0140-6736(15)00157-9
Comberiati P, Katial RK, Covar RA (2018) Bronchoprovocation testing in asthma: an update. Immunol Allergy Clin N Am 38:545–571. https://doi.org/10.1016/j.iac.2018.06.010
Cooling DS (1993) Theophylline toxicity. J Emerg Med 11:415–425
Corren J (2019) New targeted therapies for uncontrolled asthma. J Allergy Clin Immunol Pract 7:1394–1403. https://doi.org/10.1016/j.jaip.2019.03.022
Crossingham I, Evans DJ, Halcovitch NR, Marsden PA (2017) Stepping down the dose of inhaled corticosteroids for adults with asthma. Cochrane Database Syst Rev 2:CD011802. https://doi.org/10.1002/14651858.CD011802.pub2
Dahl R, Larsen BB, Venge P (2002) Effect of long-term treatment with inhaled budesonide or theophylline on lung function, airway reactivity and asthma symptoms. Respir Med 96:432–438
Davis MD, Montpetit AJ (2018) Exhaled breath condensate: an update. Immunol Allergy Clin N Am 38:667–678. https://doi.org/10.1016/j.iac.2018.06.002
Dhami S, Kakourou A, Asamoah F et al (2017) Allergen immunotherapy for allergic asthma: a systematic review and meta-analysis. Allergy 72:1825–1848. https://doi.org/10.1111/all.13208
Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ (2010) Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev 5:Cd005535. https://doi.org/10.1002/14651858.CD005535.pub2
Durack J, Lynch SV, Nariya S et al (2017) Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J Allergy Clin Immunol 140:63–75. https://doi.org/10.1016/j.jaci.2016.08.055
Erpenbeck VJ, Popov TA, Miller D et al (2016) The oral CRTh2 antagonist QAW039 (fevipiprant): a phase II study in uncontrolled allergic asthma. Pulm Pharmacol Ther 39:54–63. https://doi.org/10.1016/j.pupt.2016.06.005
European Respiratory Society (2013) The European lung white book. Respiratory health and disease in Europe. European Respiratory Society Publications, Sheffield
Fajt ML, Gelhaus SL, Freeman B et al (2013) Prostaglandin D(2) pathway upregulation: relation to asthma severity, control, and TH2 inflammation. J Allergy Clin Immunol 131:1504–1512. https://doi.org/10.1016/j.jaci.2013.01.035
FDA Drug Safety Communication (2018) FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-finds-no-significant-increase-risk-serious-asthma-outcomes
Ferraro V, Carraro S, Bozzetto S et al (2018) Exhaled biomarkers in childhood asthma: old and new approaches. Asthma Res Pract 4:9. https://doi.org/10.1186/s40733-018-0045-6
FitzGerald JM, Bleecker ER, Nair P et al (2016) Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388:2128–2141. https://doi.org/10.1016/S0140-6736(16)31322-8
FitzGerald JM, Bleecker ER, Menzies-Gow A et al (2018) Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies. Lancet Respir Med 6:51–64. https://doi.org/10.1016/S2213-2600(17)30344-2
Fitzpatrick AM, Jackson DJ, Mauger DT et al (2016) Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol 138:1608–1618 e12. https://doi.org/10.1016/j.jaci.2016.09.028
Gabet S, Just J, Couderc R et al (2016) Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants. Pediatr Allergy Immunol 27:831–837. https://doi.org/10.1111/pai.12622
Gandhi NA, Pirozzi G, Graham NMH (2017) Commonality of the IL-4/IL-13 pathway in atopic diseases. Expert Rev Clin Immunol 13:425–437. https://doi.org/10.1080/1744666X.2017.1298443
Genuneit J, Seibold AM, Apfelbacher CJ et al (2017) Overview of systematic reviews in allergy epidemiology. Allergy 72:849–856. https://doi.org/10.1111/all.13123
Global Initiative for Asthma (2017) Global strategy for asthma management and prevention. www.ginasthma.org
Global Initiative for Asthma (2018) Global strategy for asthma management and prevention. www.ginasthma.org
Global Initiative for Asthma (2019) Global strategy for asthma management and prevention. www.ginasthma.org
Gough H, Grabenhenrich L, Reich A et al (2015) Allergic multimorbidity of asthma, rhinitis and eczema over 20 years in the German birth cohort MAS. Pediatr Allergy Immunol 26:431–437. https://doi.org/10.1111/pai.12410
Guevara JP, Ducharme FM, Keren R et al (2006) Inhaled corticosteroids versus sodium cromoglycate in children and adults with asthma. Cochrane Database Syst Rev 2:CD003558. https://doi.org/10.1002/14651858.CD003558.pub2
Halim TY, Krauss RH, Sun AC, Takei F (2012) Lung natural helper cells are a critical source of Th2 cell-type cytokines in protease allergen-induced airway inflammation. Immunity 36:451–463. https://doi.org/10.1016/j.immuni.2011.12.020
Hanania NA, Noonan M, Corren J et al (2015) Lebrikizumab in moderate-to-severe asthma: pooled data from two randomised placebo-controlled studies. Thorax 70:748–756. https://doi.org/10.1136/thoraxjnl-2014-206719
Humbert M, Bousquet J, Bachert C et al (2019) IgE-mediated multimorbidities in allergic asthma and the potential for omalizumab therapy. J Allergy Clin Immunol Pract 7:1418–1429. https://doi.org/10.1016/j.jaip.2019.02.030
Jackson DJ, Makrinioti H, Rana BM et al (2014) IL-33-dependent type 2 inflammation during rhinovirus-induced asthma exacerbations in vivo. Am J Respir Crit Care Med 190:1373–1382. https://doi.org/10.1164/rccm.201406-1039OC
Jarjour NN, Erzurum SC, Bleecker ER et al (2012) Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med 185:356–362. https://doi.org/10.1164/rccm.201107-1317PP
Johansson SG, Bieber T, Dahl R et al (2004) Revised nomenclature for allergy for global use: report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 113:832–836. https://doi.org/10.1016/j.jaci.2003.12.591
Karrasch S, Linde K, Rucker G et al (2017) Accuracy of FENO for diagnosing asthma: a systematic review. Thorax 72:109–116. https://doi.org/10.1136/thoraxjnl-2016-208704
Kew KM, Dahri K (2016) Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev 1:CD011721. https://doi.org/10.1002/14651858.CD011721.pub2
Kew KM, Karner C, Mindus SM, Ferrara G (2013) Combination formoterol and budesonide as maintenance and reliever therapy versus combination inhaler maintenance for chronic asthma in adults and children. Cochrane Database Syst Rev 12:Cd009019. https://doi.org/10.1002/14651858.CD009019.pub2
Kew KM, Evans DJW, Allison DE, Boyter AC (2015) Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev 6:CD011438. https://doi.org/10.1002/14651858.CD011438.pub2
Knihtila H, Kotaniemi-Syrjanen A, Pelkonen AS et al (2018) Small airway function in children with mild to moderate asthmatic symptoms. Ann Allergy Asthma Immunol 121:451–457. https://doi.org/10.1016/j.anai.2018.07.026
Konstantinidi EM, Lappas AS, Tzortzi AS, Behrakis PK (2015) Exhaled breath condensate: technical and diagnostic aspects. Sci World J 2015:435160. https://doi.org/10.1155/2015/435160
Konstantinou GN, Xepapadaki P, Manousakis E et al (2013) Assessment of airflow limitation, airway inflammation, and symptoms during virus-induced wheezing episodes in 4- to 6-year-old children. J Allergy Clin Immunol 131:87–93 e1-5. https://doi.org/10.1016/j.jaci.2012.10.033
Korevaar DA, Westerhof GA, Wang J et al (2015) Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med 3:290–300. https://doi.org/10.1016/S2213-2600(15)00050-8
Kupczyk M, Dahlen B, Sterk PJ et al (2014) Stability of phenotypes defined by physiological variables and biomarkers in adults with asthma. Allergy 69:1198–1204. https://doi.org/10.1111/all.12445
Kuruvilla ME, Lee FE, Lee GB (2019) Understanding asthma phenotypes, endotypes, and mechanisms of disease. Clin Rev Allergy Immunol 56:219–233. https://doi.org/10.1007/s12016-018-8712-1
Kytikova O, Novgorodtseva T, Denisenko Y et al (2019) Pro-resolving lipid mediators in the pathophysiology of asthma. Medicina 55:284. https://doi.org/10.3390/medicina55060284
Lefaudeux D, De Meulder B, Loza MJ et al (2017) U-BIOPRED clinical adult asthma clusters linked to a subset of sputum omics. J Allergy Clin Immunol 139:1797–1807. https://doi.org/10.1016/j.jaci.2016.08.048
Leuppi JD (2014) Bronchoprovocation tests in asthma: direct versus indirect challenges. Curr Opin Pulm Med 20:31–36. https://doi.org/10.1097/MCP.0000000000000009
Liu AH, Babineau DC, Krouse RZ et al (2016) Pathways through which asthma risk factors contribute to asthma severity in inner-city children. J Allergy Clin Immunol 138:1042–1050. https://doi.org/10.1016/j.jaci.2016.06.060
Lundback B, Backman H, Lotvall J, Ronmark E (2016) Is asthma prevalence still increasing? Expert Rev Respir Med 10:39–51. https://doi.org/10.1586/17476348.2016.1114417
MacNeil J, Loves RH, Aaron SD (2016) Addressing the misdiagnosis of asthma in adults: where does it go wrong? Expert Rev Respir Med 10:1187–1198. https://doi.org/10.1080/17476348.2016.1242415
Matsumoto H (2014) Serum periostin: a novel biomarker for asthma management. Allergol Int 63:153–160. https://doi.org/10.2332/allergolint.13-RAI-0678
Megremis S, Niespodziana K, Cabauatan C et al (2018) Rhinovirus species-specific antibodies differentially reflect clinical outcomes in health and asthma. Am J Respir Crit Care Med 198:1490–1499. https://doi.org/10.1164/rccm.201803-0575OC
Miligkos M, Bannuru RR, Alkofide H et al (2015) Leukotriene-receptor antagonists versus placebo in the treatment of asthma in adults and adolescents: a systematic review and meta-analysis. Ann Intern Med 163:756–767. https://doi.org/10.7326/M15-1059
Momen T, Ahanchian H, Reisi M et al (2017) Comparison of interleukin-33 serum levels in asthmatic patients with a control group and relation with the severity of the disease. Int J Prev Med 8:65. https://doi.org/10.4103/ijpvm.IJPVM_179_16
Morita H, Nakae S, Saito H, Matsumoto K (2017) IL-33 in clinical practice: size matters? J Allergy Clin Immunol 140:381–383. https://doi.org/10.1016/j.jaci.2017.03.042
Mosmann TR, Cherwinski H, Bond MW et al (1986) Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357
Murray CS, Woodcock A, Custovic A (2001) The role of indoor allergen exposure in the development of sensitization and asthma. Curr Opin Allergy Clin Immunol 1:407–412. https://doi.org/10.1097/01.all.0000011053.76412.14
Nair P, Martin JG, Cockcroft DC et al (2017a) Airway hyperresponsiveness in asthma: measurement and clinical relevance. J Allergy Clin Immunol Pract 5:649–659 e2. https://doi.org/10.1016/j.jaip.2016.11.030
Nair P, Wenzel S, Rabe KF et al (2017b) Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med 376:2448–2458. https://doi.org/10.1056/NEJMoa1703501
National Asthma Education and Prevention Program, Third Expert Panel on the Diagnosis and Management of Asthma (2007) Expert Panel Report 3: guidelines for the diagnosis and management of asthma. National Heart, Lung, and Blood Institute, Bethesda. https://www.ncbi.nlm.nih.gov/books/NBK7232/
Normansell R, Walker S, Milan SJ et al (2014) Omalizumab for asthma in adults and children. Cochrane Database Syst Rev 1:CD003559. https://doi.org/10.1002/14651858.CD003559.pub4
Normansell R, Kew KM, Mathioudakis AG (2017) Interventions to improve inhaler technique for people with asthma. Cochrane Database Syst Rev 3:CD012286. https://doi.org/10.1002/14651858.CD012286.pub2
Ntontsi P, Bakakos P, Papathanasiou E et al (2018) Exhaled breath temperature in optimally treated asthmatics: severity and underlying mechanisms. J Breath Res 12:026013. https://doi.org/10.1088/1752-7163/aa9d46
O’Byrne PM, FitzGerald JM, Bateman ED et al (2018) Inhaled combined budesonide-formoterol as needed in mild asthma. N Engl J Med 378:1865–1876. https://doi.org/10.1056/NEJMoa1715274
Oksel C, Granell R, Haider S et al (2019) Distinguishing wheezing phenotypes from infancy to adolescence: a pooled analysis of five birth cohorts. Ann Am Thorac Soc 16:868–876. https://doi.org/10.1513/AnnalsATS.201811-837OC
Ortega HG, Liu MC, Pavord ID et al (2014) Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371:1198–1207. https://doi.org/10.1056/NEJMoa1403290
Papadopoulos NG, Custovic A, Cabana MD et al (2019) Pediatric asthma: an unmet need for more effective, focused treatments. Pediatr Allergy Immunol 30:7–16. https://doi.org/10.1111/pai.12990
Papi A, Brightling C, Pedersen SE, Reddel HK (2018) Asthma. Lancet 391:783–800. https://doi.org/10.1016/S0140-6736(17)33311-1
Pavord ID, Korn S, Howarth P et al (2012) Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380:651–659. https://doi.org/10.1016/S0140-6736(12)60988-X
Pavord ID, Beasley R, Agusti A et al (2018) After asthma: redefining airways diseases. Lancet 391:350–400. https://doi.org/10.1016/S0140-6736(17)30879-6
Peebles RS, Aronica MA (2019) Proinflammatory pathways in the pathogenesis of asthma. Clin Chest Med 40:29–50. https://doi.org/10.1016/j.ccm.2018.10.014
Pijnenburg MW (2019) The role of FeNO in predicting asthma. Front Pediatr 7:41. https://doi.org/10.3389/fped.2019.00041
Popov TA, Kralimarkova TZ, Labor M, Plavec D (2017) The added value of exhaled breath temperature in respiratory medicine. J Breath Res 11:034001. https://doi.org/10.1088/1752-7163/aa7801
Powell H, Gibson PG (2004) High dose versus low dose inhaled corticosteroid as initial starting dose for asthma in adults and children. Cochrane Database Syst Rev 2:CD004109. https://doi.org/10.1002/14651858.CD004109.pub2
Pruteanu AI, Chauhan BF, Zhang L et al (2014) Inhaled corticosteroids in children with persistent asthma: dose-response effects on growth. Cochrane Database Syst Rev 7:CD009878. https://doi.org/10.1002/14651858.CD009878.pub2
Psarras S, Volonaki E, Skevaki CL et al (2006) Vascular endothelial growth factor-mediated induction of angiogenesis by human rhinoviruses. J Allergy Clin Immunol 117:291–297. https://doi.org/10.1016/j.jaci.2005.11.005
Rabe KF, Nair P, Brusselle G et al (2018) Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med 378:2475–2485. https://doi.org/10.1056/NEJMoa1804093
Radhakrishnan D, Guttmann A, To T et al (2019) Generational patterns of asthma incidence among immigrants to Canada over two decades. A population-based cohort study. Ann Am Thorac Soc 16:248–257. https://doi.org/10.1513/AnnalsATS.201803-187OC
Ring J, Jutel M, Papadopoulos N et al (2018) Provocative proposal for a revised nomenclature for allergy and other hypersensitivity diseases. Allergy 73:1939–1940. https://doi.org/10.1111/all.13561
Robinson D, Humbert M, Buhl R et al (2017) Revisiting type 2-high and type 2-low airway inflammation in asthma: current knowledge and therapeutic implications. Clin Exp Allergy 47:161–175. https://doi.org/10.1111/cea.12880
Ronmark E, Bjerg A, Perzanowski M et al (2009) Major increase in allergic sensitization in schoolchildren from 1996 to 2006 in northern Sweden. J Allergy Clin Immunol 124:357–63 e1-15. https://doi.org/10.1016/j.jaci.2009.05.011
Rosenberg HF, Phipps S, Foster PS (2007) Eosinophil trafficking in allergy and asthma. J Allergy Clin Immunol 119:1303–1310. ; quiz 1311-2. https://doi.org/10.1016/j.jaci.2007.03.048
Rufo JC, Madureira J, Fernandes EO, Moreira A (2016) Volatile organic compounds in asthma diagnosis: a systematic review and meta-analysis. Allergy 71:175–188. https://doi.org/10.1111/all.12793
Saglani S, Custovic A (2019) Childhood asthma: advances using machine learning and mechanistic studies. Am J Respir Crit Care Med 199:414–422. https://doi.org/10.1164/rccm.201810-1956CI
Saglani S, Menzie-Gow AN (2019) Approaches to asthma diagnosis in children and adults. Front Pediatr 7:148. https://doi.org/10.3389/fped.2019.00148
Samolinski B, Fronczak A, Kuna P et al (2012) Prevention and control of childhood asthma and allergy in the EU from the public health point of view: Polish Presidency of the European Union. Allergy 67:726–731. https://doi.org/10.1111/j.1398-9995.2012.02822.x
Schneider A, Gindner L, Tilemann L et al (2009) Diagnostic accuracy of spirometry in primary care. BMC Pulm Med 9:31. https://doi.org/10.1186/1471-2466-9-31
Selroos O, Kupczyk M, Kuna P et al (2015) National and regional asthma programmes in Europe. Eur Respir Rev 24:474–483. https://doi.org/10.1183/16000617.00008114
Serhan CN, Levy BD (2018) Resolvins in inflammation: emergence of the pro-resolving superfamily of mediators. J Clin Invest 128:2657–2669. https://doi.org/10.1172/JCI97943
Sirois P (2019) Leukotrienes: one step in our understanding of asthma. Respir Investig 57:97–110. https://doi.org/10.1016/j.resinv.2018.12.003
Skevaki CL, Psarras S, Volonaki E et al (2012) Rhinovirus-induced basic fibroblast growth factor release mediates airway remodeling features. Clin Transl Allergy 2:14. https://doi.org/10.1186/2045-7022-2-14
Skloot GS (2016) Asthma phenotypes and endotypes: a personalized approach to treatment. Curr Opin Pulm Med 22:3–9. https://doi.org/10.1097/MCP.0000000000000225
Soto-Quiros M, Avila L, Platts-Mills TA et al (2012) High titers of IgE antibody to dust mite allergen and risk for wheezing among asthmatic children infected with rhinovirus. J Allergy Clin Immunol 129:1499–1505 e5. https://doi.org/10.1016/j.jaci.2012.03.040
Sridhar AV, McKean M (2006) Nedocromil sodium for chronic asthma in children. Cochrane Database Syst Rev 3:CD004108. https://doi.org/10.1002/14651858.CD004108.pub2
Sterk PJ, Lutter R (2014) Asthma phenotyping: TH2-high, TH2-low, and beyond. J Allergy Clin Immunol 133:395–396. https://doi.org/10.1016/j.jaci.2013.10.008
Stokes JR, Casale TB (2016) Characterization of asthma endotypes: implications for therapy. Ann Allergy Asthma Immunol 117:121–125. https://doi.org/10.1016/j.anai.2016.05.016
Sullivan A, Hunt E, MacSharry J, Murphy DM (2016) The microbiome and the pathophysiology of asthma. Respir Res 17:163. https://doi.org/10.1186/s12931-016-0479-4
Teague WG, Phillips BR, Fahy JV et al (2018) Baseline features of the Severe Asthma Research Program (SARP III) cohort: differences with age. J Allergy Clin Immunol Pract 6:545–554 e4. https://doi.org/10.1016/j.jaip.2017.05.032
Tee AKH, Koh MS, Gibson PG et al (2007) Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma. Cochrane Database Syst Rev 3:CD001281. https://doi.org/10.1002/14651858.CD001281.pub2
To T, Stanojevic S, Moores G et al (2012) Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health 12:204. https://doi.org/10.1186/1471-2458-12-204
Toppila-Salmi S, Huhtala H, Karjalainen J et al (2015) Sensitization pattern affects the asthma risk in Finnish adult population. Allergy 70:1112–1120. https://doi.org/10.1111/all.12670
Toppila-Salmi S, Chanoine S, Karjalainen J et al (2019) Risk of adult-onset asthma increases with the number of allergic multimorbidities and decreases with age. Allergy 74:2406–2416. https://doi.org/10.1111/all.13971
Turner S (2015) Exhaled nitric oxide and the management of childhood asthma--yet another promising biomarker “has been” or a misunderstood gem. Paediatr Respir Rev 16:88–96. https://doi.org/10.1016/j.prrv.2014.07.005
Ullmann N, Bossley CJ, Fleming L et al (2013) Blood eosinophil counts rarely reflect airway eosinophilia in children with severe asthma. Allergy 68:402–406. https://doi.org/10.1111/all.12101
van Vliet D, Smolinska A, Jobsis Q et al (2017) Can exhaled volatile organic compounds predict asthma exacerbations in children? J Breath Res 11:016016. https://doi.org/10.1088/1752-7163/aa5a8b
Veldhoen M (2017) Interleukin 17 is a chief orchestrator of immunity. Nat Immunol 18:612–621. https://doi.org/10.1038/ni.3742
Vezina K, Chauhan BF, Ducharme FM (2014) Inhaled anticholinergics and short-acting beta(2)-agonists versus short-acting beta2-agonists alone for children with acute asthma in hospital. Cochrane Database Syst Rev 7:CD010283. https://doi.org/10.1002/14651858.CD010283.pub2
Vos T, Flaxman AD, Naghavi M et al (2012) Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2163–2196. https://doi.org/10.1016/S0140-6736(12)61729-2
Wenzel SE (2012) Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 18:716–725. https://doi.org/10.1038/nm.2678
Westerhof GA, Korevaar DA, Amelink M, de Nijs SB, de Groot JC, Wang J, Weersink EJ, ten Brinke A, Bossuyt PM, Bel EH (2015) Biomarkers to identify sputum eosinophilia in different adult asthma phenotypes. Eur Respir J 46:688–696. https://doi.org/10.1183/09031936.00012415
Xepapadaki P, Papadopoulos NG, Bossios A et al (2005) Duration of postviral airway hyperresponsiveness in children with asthma: effect of atopy. J Allergy Clin Immunol 116:299–304. https://doi.org/10.1016/j.jaci.2005.04.007
Xepapadaki P, Xatziioannou A, Chatzicharalambous M et al (2010) Exhaled breath temperature increases during mild exacerbations in children with virus-induced asthma. Int Arch Allergy Immunol 153:70–74. https://doi.org/10.1159/000301581
Xepapadaki P, Bachert C, Finotto S et al (2018) Contribution of repeated infections in asthma persistence from preschool to school age: design and characteristics of the PreDicta cohort. Pediatr Allergy Immunol 29:383–393. https://doi.org/10.1111/pai.12881
Zhang L, Prietsch SOM, Ducharme FM (2014) Inhaled corticosteroids in children with persistent asthma: effects on growth. Cochrane Database Syst Rev 7:CD009471. https://doi.org/10.1002/14651858.CD009471.pub2
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Papadopoulos, N.G., Miligkos, M., Xepapadaki, P. (2021). A Current Perspective of Allergic Asthma: From Mechanisms to Management. In: Traidl-Hoffmann, C., Zuberbier, T., Werfel, T. (eds) Allergic Diseases – From Basic Mechanisms to Comprehensive Management and Prevention . Handbook of Experimental Pharmacology, vol 268. Springer, Cham. https://doi.org/10.1007/164_2021_483
Download citation
DOI: https://doi.org/10.1007/164_2021_483
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-84047-1
Online ISBN: 978-3-030-84048-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)